Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors

Investigational New Drugs

Volumn 28, Issue 2, 2010, Pages 163-170

  Oostendorp, R L ^a   Witteveen, P O ^b   Schwartz, B ^c   Vainchtein, L D ^d   Schot, M ^a   Nol, A ^a   Rosing, H ^d   Beijnen, J H ^d   Voest, E E ^b   Schellens, J H M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Ziopharm Oncology   (United States)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Capsules; D 24581; Dose escalation; Indibulin; Oral; Phase I

Indexed keywords

AEROSIL; ANTINEOPLASTIC AGENT; D 24851; GELATIN; INDIBULIN; MAGNESIUM STEARATE; MICROCRYSTALLINE CELLULOSE; POLYSORBATE 80; STARCH; UNCLASSIFIED DRUG; ZIO 301;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BLURRED VISION; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STORAGE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE; GASTRITIS; HUMAN; HYPOPHOSPHATEMIA; HYPOSMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE STRAIN; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RHINOPHARYNGITIS; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; STOMATITIS; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL ACUITY; XEROSTOMIA;

ACETAMIDES; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS; TIME FACTORS;

EID: 77952241570     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9244-6     Document Type: Article

References (15)

1. MA Jordan 2002 Mechanism of action of antitumor drugs that interact with microtubules and tubulin Curr Med Chem Anticancer Agents 2 1 17 10.2174/1568011023354290 10.2174/1568011023354290 1:CAS:528:DC%2BD38XislGmurg%3D 12678749
2. G Bacher B Nickel P Emig, et al. 2001 D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity Cancer Res 61 392 399 1:CAS:528:DC%2BD3MXlvVSjsg%3D%3D 11196193
3. Baxter (2005) Investigator's brochure indibulin
4. M Hussain AJ Wozniak MB Edelstein 1993 Neurotoxicity of antineoplastic agents Crit Rev Oncol Hematol 14 61 75 10.1016/1040-8428(93) 90006-P 10.1016/1040-8428(93)90006-P 1:STN:280:DyaK3szosVOntQ%3D%3D 8373541
5. PH Hilkens J Verweij CJ Vecht, et al. 1997 Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere) Ann Oncol 8 187 190 10.1023/A:1008245400251 10.1023/A:1008245400251 1:STN:280:DyaK2s3kslKjsA%3D%3D 9093729 (Pubitemid 27112888)
6. RJ Freilich C Balmaceda AD Seidman, et al. 1996 Motor neuropathy due to docetaxel and paclitaxel Neurology 47 115 118 1:CAS:528:DyaK28XkvFalt7o%3D 8710063
7. AJ Windebank 1999 Chemotherapeutic neuropathy Curr Opin Neurol 12 565 571 10.1097/00019052-199910000-00010 10.1097/00019052-199910000-00010 1:STN:280:DC%2BD3c%2FlvVCitg%3D%3D 10590893 (Pubitemid 30028616)
8. EK Rowinsky 1997 The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents Annu Rev Med 48 353 374 10.1146/annurev.med.48.1.353 10.1146/annurev.med.48.1.353 1:CAS:528: DyaK2sXhtFOmsLs%3D 9046968 (Pubitemid 27101837)
9. JH Schiller 1998 Role of taxanes in lung-cancer chemotherapy Cancer Invest 16 471 477 10.3109/07357909809011701 10.3109/07357909809011701 1:CAS:528:DyaK1cXmvVOmsr0%3D 9774954
10. IE Kuppens PO Witteveen M Schot, et al. 2007 Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors Invest New Drugs 25 227 235 10.1007/s10637-006-9027-2 10.1007/s10637-006-9027-2 1:CAS:528:DC%2BD2sXltlartrk%3D 17146730 (Pubitemid 46774701)
11. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 doi:10.1093/jnci/92.3.205 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
12. E Stokvis LG Nan-Offeringa M Ouwehand, et al. 2004 Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry Rapid Commun Mass Spectrom 18 1465 1471 10.1002/rcm.1493 10.1002/rcm.1493 1:CAS:528:DC%2BD2cXls1Grsbo%3D 15216507 (Pubitemid 38868747)
13. SA Veltkamp H Rosing AD Huitema, et al. 2007 Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours Cancer Chemother Pharmacol 60 635 642 10.1007/s00280-006- 0405-4 10.1007/s00280-006-0405-4 1:CAS:528:DC%2BD2sXovFSrsbY%3D 17205304 (Pubitemid 47247275)
14. SA Veltkamp C Alderden-Los A Sharma, et al. 2007 A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application Cancer Chemother Pharmacol 59 43 50 10.1007/s00280-006-0245-2 10.1007/s00280-006-0245-2 1:CAS:528:DC%2BD28Xht1entL%2FF 16680462 (Pubitemid 44796101)
15. SA Veltkamp B Thijssen JS Garrigue, et al. 2006 A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer Br J Cancer 95 729 734 10.1038/sj.bjc.6603312 10.1038/sj.bjc.6603312 1:CAS:528:DC%2BD28Xptlaltbc%3D 16926835 (Pubitemid 44373489)